title: Folate and choline metabolism gene variants and development of uterine cervical carcinoma.
abstract: OBJECTIVE
  It has been reported that aberrant DNA methylation can be associated with HPV infection and cervical tumorigenesis. The aim of this study was to evaluate the possibility that polymorphic variants of genes that may affect DNA methylation status are associated with the risk of cervical cancer in the Polish population.
  
  
  METHODS
  Employing PCR-RFLPs and HRM analyses, we examined the prevalence of BHMT Arg239Gln (rs3733890), MTR Asp919Gly (rs1805087), MTHFR Ala222Val (rs1801133), MTHFD1 Arg653Gln (rs2236225) and MTRR Ile22Met (rs1801394) genotypes and alleles in patients with advanced cervical cancer (n=124) and controls (n=168).
  
  
  RESULTS
  The odds ratio (OR) for BHMT Gln/Gln genotype was 0.433 (95% CI=0.1780-1.054; p=0.0602). The OR for patients having the BHMT Arg/Gln or Gln/Gln genotypes was 0.579 (95% CI=0.3622-0.924; p=0.0216). We also observed a significantly higher frequency of the BHMT 239Gln allele in controls than in patients, p=0.0165. The genotype and allele frequencies of the MTR Asp919Gly, MTHFR Ala222Val, MTHFD1 Arg653Gln and MTRR Ile22Met gene variants did not display statistical differences between patients with cervical cancer and controls. We also did not find a significant association between the distribution of any genotypes or alleles and cancer characteristics.
  
  
  CONCLUSIONS
  Our results might suggest the protective role of the BHMT 239Gln variant in cervical cancer incidence.
authors.affiliation: Department of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 6 Swiecickiego St., 60-781 Poznan, Poland.
authors.forename: Adrianna
authors.initials: A
authors.lastname: Mostowska
authors.forename: Martyna
authors.initials: M
authors.lastname: Myka
authors.forename: Margarita
authors.initials: M
authors.lastname: Lianeri
authors.forename: Andrzej
authors.initials: A
authors.lastname: Roszak
authors.forename: Pawel P
authors.initials: PP
authors.lastname: Jagodziński
mesh_terms: D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2) / Q000235:genetics; D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / Q000235:genetics; D000328:Adult; D000483:Alleles; D050940:Betaine-Homocysteine S-Methyltransferase / Q000235:genetics; D002794:Choline / Q000235:genetics*; D005260:Female; D005287:Ferredoxin-NADP Reductase / Q000235:genetics; D005492:Folic Acid / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008754:Methylenetetrahydrofolate Dehydrogenase (NADP) / Q000235:genetics; D008875:Middle Aged; D015778:Minor Histocompatibility Antigens; D008954:Models, Biological; D016017:Odds Ratio; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D002583:Uterine Cervical Neoplasms / Q000235:genetics*
chemical_list: D015778:Minor Histocompatibility Antigens; D005492:Folic Acid; C111241:methionine synthase reductase; D005287:Ferredoxin-NADP Reductase; D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2); C539735:MTHFD1 protein, human; D008754:Methylenetetrahydrofolate Dehydrogenase (NADP); D013766:5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; C494548:BHMT protein, human; D050940:Betaine-Homocysteine S-Methyltransferase; D002794:Choline